1,2 Initial results demonstrated a 14% reduction in MACE with oral semaglutide
Without volunteers willing to participate in clinical trials, no new medications could ever reach patients in need
The response still depends on a functional hypothalamic-pituitary axis and the ability of pituitary somatotroph cells to produce and release GH
Furthermore, the effects of GLP-1 on HF, especially established/symptomatic HF, are poorly understood and has been a subject of active debate [6,7,8,9]
The results of Semaglutide GLP-1 are among the most efficient and substantial of any weight loss drug available
Patients message through the portal and typically get business-day replies